| Adenocarcinoma altered in cohorts of …ALTERED_INderived200 of 1,234show all (up to 200) |
|---|
| ← altered in cohorts of | COL7A1 450 / 536 cases (84 %) · ssm · TCGA-KIRC · largest of 3 cohorts | — | — | Clear Cell Renal Cell Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | GLB1 450 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLXNB1 450 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATRIP 449 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC51 449 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDC25A 449 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CELSR3 449 / 536 cases (84 %) · ssm · TCGA-KIRC · largest of 4 cohorts | — | — | Clear Cell Renal Cell Carcinoma | 4 | Observed | gdc | graph → |
| ← altered in cohorts of | FBXW12 449 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HHATL 449 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IP6K2 449 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NCKIPSD 449 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PFKFB4 449 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRKAR2A 449 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PTH1R 449 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SCN5A 449 / 536 cases (84 %) · ssm · TCGA-KIRC · largest of 4 cohorts | — | — | Clear Cell Renal Cell Carcinoma | 4 | Observed | gdc | graph → |
| ← altered in cohorts of | SHISA5 449 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC26A6 449 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMA7 449 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM89 449 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TREX1 449 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UCN2 449 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UQCRC1 449 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VIPR1 449 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ABHD14A 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ABHD14A-ACY1 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ABHD14B 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ABHD5 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ACY1 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALAS1 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ANO10 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | APEH 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARIH2 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BSN 448 / 536 cases (84 %) · ssm · TCGA-KIRC · largest of 3 cohorts | — | — | Clear Cell Renal Cell Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | C3orf62 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C3orf84 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAMP 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC13 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC71 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCRL2 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DAG1 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DALRD3 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DCAF1 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DOCK3 448 / 536 cases (84 %) · ssm · TCGA-KIRC · largest of 3 cohorts | — | — | Clear Cell Renal Cell Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | DUSP7 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GNAI2 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR62 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPX1 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IHO1 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IQCF1 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IQCF2 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IQCF3 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IQCF5 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHDC8B 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHL40 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LAMB2 448 / 536 cases (84 %) · ssm · TCGA-KIRC · largest of 2 cohorts | — | — | Clear Cell Renal Cell Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LARS2 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LIMD1 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LTF 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MST1 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NDUFAF3 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NICN1 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NKTR 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NME6 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | P4HTM 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PARP3 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PCBP4 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDCD6IP 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | POC1A 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PTPN23 448 / 536 cases (84 %) · ssm · TCGA-KIRC · largest of 2 cohorts | — | — | Clear Cell Renal Cell Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | QARS1 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | QRICH1 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL29 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RRP9 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SCN11A 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SEC22C 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC25A20 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SNRK 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPCS1 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPINK8 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SS18L2 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SUSD5 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TCTA 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TLR9 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TOPAZ1 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | USP19 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | USP4 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WDR6 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | XIRP1 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBTB47 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF589 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF620 448 / 536 cases (84 %) · ssm · TCGA-KIRC | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM189B 276 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | DCST2 275 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA1 275 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | MTX1 275 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBTB7B 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGEF2 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DPM3 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA4 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | KHDC4 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 3 cohorts | — | — | Hepatocellular Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | KRTCAP2 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LENEP 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MUC1 274 / 377 cases (73 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CKS1B 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DAP3 273 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 3 cohorts | — | — | Hepatocellular Carcinoma | 3 | Observed | gdc | graph → |
| ← altered in cohorts of | PYGO2 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RXFP4 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SHC1 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC27A3 273 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LMNA 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MEX3A 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PMVK 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RYR2 413 / 573 cases (72 %) · ssm · TCGA-LUAD · largest of 25 cohorts | — | — | Lung Adenocarcinoma | 25 | Observed | gdc | graph → |
| ← altered in cohorts of | CCT3 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ETV3L 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GATAD2B 271 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ISG20L2 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LAMTOR2 271 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC71 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MNDA 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NTRK1 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PMF1 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RAB25 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SEMA4A 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SH2D2A 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SSR2 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM79 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBE2Q1 271 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | UBQLN4 271 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGAP30 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ATF6 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | CRABP2 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | ETV3 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR3B 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | GLMP 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HAPLN2 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | HDGF 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NIT1 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OR6Y1 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PAQR6 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SNAPIN 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | USP21 270 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | FLG 406 / 573 cases (71 %) · ssm · TCGA-LUAD · largest of 21 cohorts | — | — | Lung Adenocarcinoma | 21 | Observed | gdc | graph → |
| ← altered in cohorts of | USH2A 402 / 573 cases (70 %) · ssm · TCGA-LUAD · largest of 25 cohorts | — | — | Lung Adenocarcinoma | 25 | Observed | gdc | graph → |
| ← altered in cohorts of | PRPF3 35 / 50 cases (70 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPTA1 400 / 573 cases (70 %) · ssm · TCGA-LUAD · largest of 22 cohorts | — | — | Lung Adenocarcinoma | 22 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR3A 60 / 87 cases (69 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HSPA6 60 / 87 cases (69 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | VHL 642 / 943 cases (68 %) · ssm · ccrcc_sjuh_2023 · largest of 12 cohorts | — | — | Clear Cell Renal Cell Carcinoma | 12 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ANP32E 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | APH1A 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf54 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CA14 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CIART 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CTXND2 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRPS21 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR2B 59 / 87 cases (68 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FLG2 388 / 573 cases (68 %) · ssm · TCGA-LUAD · largest of 10 cohorts | — | — | Lung Adenocarcinoma | 10 | Observed | gdc | graph → |
| ← altered in cohorts of | HRNR 383 / 573 cases (67 %) · ssm · TCGA-LUAD · largest of 9 cohorts | — | — | Lung Adenocarcinoma | 9 | Observed | gdc | graph → |
| ← altered in cohorts of | ASH1L 382 / 573 cases (67 %) · ssm · TCGA-LUAD · largest of 4 cohorts | — | — | Lung Adenocarcinoma | 4 | Observed | gdc | graph → |
| ← altered in cohorts of | CD84 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR2A 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRLA 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRLB 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | JTB 58 / 87 cases (67 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | RAB13 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPS27 58 / 87 cases (67 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF6 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC39A1 58 / 87 cases (67 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | TNN 382 / 573 cases (67 %) · ssm · TCGA-LUAD · largest of 7 cohorts | — | — | Lung Adenocarcinoma | 7 | Observed | gdc | graph → |
| ← altered in cohorts of | TNR 382 / 573 cases (67 %) · ssm · TCGA-LUAD · largest of 6 cohorts | — | — | Lung Adenocarcinoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | UAP1 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UHMK1 58 / 87 cases (67 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf56 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GABPB2 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LYSMD1 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLEKHO1 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSMD4 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RFX5 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMOD4 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFAIP8L2 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS72 33 / 50 cases (66 %) · ssm · CDDP_EAGLE-1 | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf189 57 / 87 cases (66 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf226 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD48 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DDR2 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DUSP12 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HAX1 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGSF8 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IL6R 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ILF2 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | INTS3 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNJ10 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNJ9 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LY9 57 / 87 cases (66 %) · ssm · APOLLO-LUAD · largest of 2 cohorts | — | — | Lung Adenocarcinoma | 2 | Observed | gdc | graph → |
| ← altered in cohorts of | NOS1AP 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | S100A1 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | S100A13 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SH2D1B 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLAMF1 57 / 87 cases (66 %) · ssm · APOLLO-LUAD | — | — | Lung Adenocarcinoma | 1 | Observed | gdc | graph → |